Waki

Researchers are evaluating the safety and effectiveness of talquetamab, a humanized bispecific antibody, in adults with relapsed or refractory multiple myeloma. This study focuses on participants who have measurable disease and seeks to determine the recommended Phase 2 dose(s) of talquetamab. It is an open-label, dose escalation trial designed to treat hematological malignancies, specifically multiple myeloma. Participants will receive talquetamab administered subcutaneously (under the skin) and continue treatment until their disease progresses. The study includes multiple cohorts based on disease measurability assessed by either central or local laboratory testing. The investigational drug is given repeatedly under careful monitoring as part of this Phase 2 study. Throughout the study, participants will undergo regular assessments to monitor response to treatment, with the primary outcome being the overall response rate measured for up to nearly three years. Other evaluations include performance status checks, pregnancy testing for women of childbearing potential, and close observation for any side effects. Safety and treatment effectiveness will be followed until disease progression or other study endpoints.